AbCellera (Nasdaq: ABCL) plans August 10 ABCL635 menopause trial readout
Rhea-AI Filing Summary
AbCellera Biologics Inc. announced it will release top-line data from its Phase 2 trial of ABCL635 for the treatment of moderate-to-severe vasomotor symptoms due to menopause on August 10, 2026, and will host an investor conference call that morning.
ABCL635 is described as a potential first-in-class, non-hormonal antibody targeting NK3R, a clinically validated G protein-coupled receptor expressed on KNDy neurons in the hypothalamus. The Phase 2 trial (NCT07118891) is a multicenter, randomized, double-blind, placebo-controlled study in approximately 80 postmenopausal women evaluating reduction in the frequency and severity of vasomotor symptoms. ABCL635 is the first program from AbCellera’s GPCR and ion channel platform to enter the clinic, having done so in July 2025.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Phase: Phase 2
Trial enrollment: approximately 80 postmenopausal women
Clinical trial identifier: NCT07118891
+4 more
7 metrics
Phase
Phase 2
Development stage of ABCL635 trial for vasomotor symptoms due to menopause
Trial enrollment
approximately 80 postmenopausal women
Planned enrollment for the ABCL635 Phase 2 randomized trial
Clinical trial identifier
NCT07118891
Registry identifier for the ABCL635 Phase 2 trial
Data release date
August 10, 2026
Scheduled date for release of top-line ABCL635 Phase 2 data
Conference call time (PT)
4:30 a.m. Pacific Time
Start time of investor conference call discussing ABCL635 data
Conference call time (ET)
7:30 a.m. Eastern Time
Corresponding Eastern Time for the investor conference call
Clinic entry date
July 2025
Month and year ABCL635 first entered clinical development
Key Terms
vasomotor symptoms (VMS), G protein-coupled receptor (GPCR), KNDy neurons, double-blind, placebo-controlled, +1 more
5 terms
vasomotor symptoms (VMS) medical
"for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause"
Vasomotor symptoms are sudden changes in body temperature regulation, most commonly experienced as hot flashes and night sweats, caused by brief shifts in blood flow and nervous system signals that control heat. They matter to investors because they create demand for drugs, therapies and devices, influence healthcare spending and clinical trial activity, and can affect workforce productivity—making them a clear market and regulatory opportunity.
G protein-coupled receptor (GPCR) medical
"a clinically validated G protein-coupled receptor (GPCR) expressed on KNDy neurons"
G protein-coupled receptors are a large family of proteins on the surface of cells that act like sensors or doorbells: they detect hormones, neurotransmitters and other signals outside the cell and trigger internal switch proteins to change the cell’s behavior. They matter to investors because a large portion of approved drugs and experimental medicines work by turning these sensors on or off, so discoveries, trial results or approvals involving GPCRs can significantly affect a biotech or pharmaceutical company’s value.
KNDy neurons medical
"expressed on KNDy neurons in the infundibular nucleus of the hypothalamus"
double-blind, placebo-controlled medical
"a multicenter, randomized, double-blind, placebo-controlled trial with approximately 80"
A clinical trial design in which participants are randomly assigned to receive either the experimental treatment or an inactive substitute (a placebo), and neither the participants nor the researchers know who is receiving which. This setup limits bias and makes it far easier to tell whether a drug or intervention truly works, similar to a blind taste test, so results carry more weight for regulatory decisions and for investors assessing a product’s commercial prospects.
first-in-class antibody medical
"ABCL635 is a potential first-in-class antibody drug for the non-hormonal treatment"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did AbCellera (ABCL) announce about its ABCL635 Phase 2 trial?
AbCellera announced it will release top-line Phase 2 data for ABCL635 in menopause-related vasomotor symptoms on August 10, 2026, followed by an investor conference call and webcast the same morning for analysts and shareholders.
When will AbCellera (ABCL) hold the investor call on ABCL635 results?
The investor call will be held at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) on August 10, 2026, with a live webcast and replay available via AbCellera’s Investor Relations website for interested investors.
What is ABCL635 in AbCellera (ABCL)’s pipeline?
ABCL635 is a potential first-in-class, non-hormonal antibody for treating moderate-to-severe vasomotor symptoms due to menopause, targeting NK3R, a clinically validated G protein-coupled receptor expressed on specialized KNDy neurons in the hypothalamus.
How is AbCellera (ABCL)’s Phase 2 trial of ABCL635 designed?
The Phase 2 trial (bNCT07118891) is a multicenter, randomized, double-blind, placebo-controlled study with approximately 80 postmenopausal women, designed to evaluate how ABCL635 reduces the frequency and severity of moderate-to-severe vasomotor symptoms.
What therapeutic area is AbCellera (ABCL) targeting with ABCL635?
ABCL635 targets women’s health, specifically moderate-to-severe vasomotor symptoms (hot flashes) due to menopause, as part of AbCellera’s broader focus on first-in-class antibody medicines in endocrinology, women’s health, immunology, and oncology.
When did AbCellera (ABCL) first bring ABCL635 into clinical trials?
ABCL635 entered the clinic in July 2025 as the first program from AbCellera’s GPCR and ion channel platform, marking the transition of this discovery platform into a clinical-stage pipeline asset for menopause-related vasomotor symptom treatment.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 7, 2026
__________________________________________
(Exact name of registrant as specified in its charter)
__________________________________________
| Not Applicable | ||||||||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||||||
150 W 4th Avenue | |||||
| (Address of registrant’s principal executive office) | (Zip code) | ||||
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01 Other Events
On August 7, 2026, AbCellera Biologics Inc. (the “Company”) issued a press release announcing it will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause on Monday, August 10, 2026 and hold an investor conference call at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) the same day.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press Release issued by AbCellera Biologics Inc. on August 7, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded as Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 7, 2026 | ABCELLERA BIOLOGICS INC. | |||||||
| By: | /s/ Carl L. G. Hansen | |||||||
| Carl L. G. Hansen, Ph.D. | ||||||||
Chief Executive Officer and Director (Principal Executive Officer) | ||||||||
150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to- Severe VMS Due to Menopause on Monday, August 10, 2026 2026-08-07 Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ET VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause before the market opens on Monday, August 10, 2026 and hold an investor conference call at 4:30 a.m. Paci�c Time (7:30 a.m. Eastern Time) the same day. A live audio webcast of the investor conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call. About ABCL635 ABCL635 is a potential �rst-in-class antibody drug for the non-hormonal treatment of moderate-to-severe VMS, commonly known as hot �ashes, due to menopause. ABCL635 speci�cally targets NK3R, a clinically validated G protein-coupled receptor (GPCR) expressed on KNDy neurons in the infundibular nucleus of the hypothalamus. 1
ABCL635 is the �rst program from AbCellera’s GPCR and ion channel platform to advance into the pipeline, entering the clinic in July 2025. Additional details are available at www.abcellera.com/pipeline. The Phase 2 trial of ABCL635 (NCT07118891) is a multicenter, randomized, double-blind, placebo-controlled trial with approximately 80 postmenopausal women designed to evaluate the e�cacy of ABCL635 in reducing the frequency and severity of moderate-to-severe VMS. About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing �rst- in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For more information, please visit www.abcellera.com. Inquiries Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774 Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116 Source: AbCellera Biologics Inc. 2